Compare GATX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GATX | LNTH |
|---|---|---|
| Founded | 1898 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.7B |
| IPO Year | 1994 | 2014 |
| Metric | GATX | LNTH |
|---|---|---|
| Price | $177.20 | $100.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $215.50 | $87.00 |
| AVG Volume (30 Days) | 156.5K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 17.22 | N/A |
| EPS | ★ 5.19 | 2.91 |
| Revenue | ★ $1,740,400,000.00 | $343,374,000.00 |
| Revenue This Year | $42.21 | N/A |
| Revenue Next Year | $3.35 | $14.19 |
| P/E Ratio | ★ $33.44 | $34.65 |
| Revenue Growth | ★ 9.77 | 3.62 |
| 52 Week Low | $150.42 | $49.67 |
| 52 Week High | $205.56 | $111.86 |
| Indicator | GATX | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 46.25 |
| Support Level | $166.01 | $100.51 |
| Resistance Level | $175.37 | $102.66 |
| Average True Range (ATR) | 3.29 | 0.53 |
| MACD | -0.53 | 0.15 |
| Stochastic Oscillator | 14.56 | 50.86 |
GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.